A Phase 4 interventional study of Memantine and placebo in Alzheimer's Disease, sponsored by Forest Laboratories. Completed at 25 sites in 3 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2009-12-24.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing memantine in Alzheimer Disease — 1 open to participants now, 2 under way, none of them phase 3. Memantine · Alzheimer Disease.
Among the 34 studies testing memantine in Alzheimer Disease, this one is the 7th largest by enrollment, is one of 6 that started in 2007, is one of 21 in phase 4, and was the 9th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →1 of the 34 studies testing memantine in Alzheimer Disease is open now, in 1 country. Recruiting first, the newest first:
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–32
By country, each count listing its studies:
Memantine: first FDA approval 2003 (NAMENDA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 9 · Phase 4 21
First in 2003; this study’s year is marked. 6 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 265 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 90 across the 34 interventional studies. Of the 28 that completed or were terminated, 15 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
27 studies in Alzheimer Disease by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 24 finished, 6 (25%) have results posted.
Among the 27 studies in Alzheimer Disease by AbbVie, this one is the 11th largest by enrollment, is the only one that started in 2007, is one of 2 in phase 4, and was the 5th registered.
AbbVie’s Alzheimer Disease studies by the year they started, since 2003.
1 of the studies testing memantine in Alzheimer Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05063851University of VirginiaThe Use of Memantine for Prevention of Alzheimer's Disease | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies testing memantine in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 27 in Alzheimer Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the effect of memantine versus placebo on functional communication in patients with Alzheimer's Disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Memantine 20mg (10mg twice daily) oral administration for 12 weeks
Drug: Memantine
Placebo oral administration twice daily for 12 weeks
Drug: placebo
Memantine 20mg (10mg twice daily) oral administration for 12 weeks
Also known as: Namenda®
Placebo oral administration twice daily for 12 weeks
Change From Baseline in Functional Linguistic Communication Inventory (FLCI) at Week 12
FLCI is a standardized \& validated instrument for evaluating functional communication in pts with moderate-to-severe Alzheimer's that can be used to obtain Baseline information \& to track patients' capabilities thereafter. The FLCI evaluates 10 areas: greeting and naming, answering questions, writing, sign comprehension, object-to-picture matching, word reading and comprehension, following commands, pantomime, gesture, and conversation. The FLCI total score ranges from 0 to 87, a higher score denotes better functional communication, and takes approximately 30 minutes to complete.
Time frame: Baseline to Week 12
Change From Baseline in American Speech-Language-Hearing Association Functional Assessment of Communication Skills for Adults (ASHA FACS) [Total Score of Social Communication and Communication of Basic Needs Subscores] at Week 12
The ASHA FACS assesses \& measures functional communication skills of adults with speech, language, \& cognitive communication disorders. The measure, which comprises 43 items and takes approximately 20 minutes to complete, assesses functional communication in four areas: social communication; communication of basic needs; reading, writing, and number concepts; and daily planning. Total score of subdomains \[Social Communication and Communication of Basic Needs\] ranges from 0-196. A higher score denotes better communication.
Time frame: Baseline to Week 12
The recruitment period was from May 24, 2007 to July 29, 2008 at 25 centers in three countries \[14 in Australia, 3 in New Zealand, 8 in South Africa\].
| Milestone | Placebo | Memantine |
|---|---|---|
| Started | 129 | 135 |
| Completed | 120 | 131 |
| Not completed | 9 | 4 |
| Withdrew: Adverse event | 4 | 3 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 |
FLCI is a standardized \& validated instrument for evaluating functional communication in pts with moderate-to-severe Alzheimer's that can be used to obtain Baseline information \& to track patients' capabilities thereafter. The FLCI evaluates 10 areas: greeting and naming, answering questions, writing, sign comprehension, object-to-picture matching, word reading and comprehension, following commands, pantomime, gesture, and conversation. The FLCI total score ranges from 0 to 87, a higher score denotes better functional communication, and takes approximately 30 minutes to complete.
| Units on a scale | Placebo | Memantine |
|---|---|---|
| Change From Baseline in Functional Linguistic Communication Inventory (FLCI) at Week 12 | -0.6 ± 0.59 | 0.7 ± 0.57 |
The ASHA FACS assesses \& measures functional communication skills of adults with speech, language, \& cognitive communication disorders. The measure, which comprises 43 items and takes approximately 20 minutes to complete, assesses functional communication in four areas: social communication; communication of basic needs; reading, writing, and number concepts; and daily planning. Total score of subdomains \[Social Communication and Communication of Basic Needs\] ranges from 0-196. A higher score denotes better communication.
| Units on a scale | Placebo | Memantine |
|---|---|---|
| Change From Baseline in American Speech-Language-Hearing Association Functional Assessment of Communication Skills for Adults (ASHA FACS) [Total Score of Social Communication and Communication of Basic Needs Subscores] at Week 12 | -5.3 ± 2.06 | 0.5 ± 1.99 |
Collected over Occurring on or after the date of the first dose of double-blind study medication and within 30 days of the date of last dose of double-blind study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 13/129 (10.1%) | 2/129 (1.6%) |
| Memantine | — | 4/135 (3%) | 7/135 (5.2%) |
| Event | Placebo | Memantine |
|---|---|---|
| SyncopeNervous system disorders | 2/129 | 0/135 |
| Urinary Tract InfectionInfections and infestations | 2/129 | 0/135 |
| Atrioventricular Block First DegreeCardiac disorders | 1/129 | 0/135 |
| Bile Duct StoneHepatobiliary disorders | 1/129 | 0/135 |
| Cerebellar InfarctionNervous system disorders | 1/129 | 0/135 |
| ConstipationGastrointestinal disorders | 1/129 | 0/135 |
| FallInjury, poisoning and procedural complications | 1/129 | 0/135 |
| Femur FractureInjury, poisoning and procedural complications | 1/129 | 0/135 |
| Gastric UlcerGastrointestinal disorders | 1/129 | 0/135 |
| Gastrointeritis YersiniaInfections and infestations | 1/129 | 0/135 |
| Event | Placebo | Memantine |
|---|---|---|
| DizzinessNervous system disorders | 2/129 | 7/135 |
| Age, Customized(participants) | Placebo | Memantine | Total |
|---|---|---|---|
| <=64 years | 19 | 13 | 32 |
| 65-74 years | 33 | 51 | 84 |
| 75-84 years | 59 | 56 | 115 |
| >=85 years | 18 | 15 | 33 |
| Age Continuous(years) | Placebo | Memantine | Total |
|---|---|---|---|
| Mean | 75.1 ± 8.68 | 74.8 ± 8.05 | 74.9 ± 8.35 |
| Sex: Female, Male(Participants) | Placebo | Memantine | Total |
|---|---|---|---|
| Female | 74 | 80 | 154 |
| Male | 55 | 55 | 110 |
| Region of Enrollment(participants) | Placebo | Memantine | Total |
|---|---|---|---|
| Australia | 55 | 55 | 110 |
| South Africa | 58 | 62 | 120 |
| New Zealand | 16 | 18 | 34 |
The record gives a start of Apr 2007, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Memantine